Hirofumi Makino
Okayama University
Internal medicineUrologyEndocrinologySurgeryPathologyRenal functionChemistryImmunologyGlomerular basement membraneKidney diseaseProteinuriaDiabetic nephropathyKidneyGlomerulonephritisNephropathyNephrologyDiabetes mellitusMedicineBiologyGastroenterology
918Publications
98H-index
26.2kCitations
Publications 912
Newest
#1Megumi Oshima (Kanazawa University)H-Index: 7
#2Tadashi Toyama (Kanazawa University)H-Index: 23
Last. Tetsuya BabazonoH-Index: 30
view all 0 authors...
Introduction null Changes in albuminuria or estimated glomerular filtration rate (eGFR) can be used as a surrogate endpoint of end-stage kidney disease (ESKD) in people with type 2 diabetes. We investigated whether the combined changes in albuminuria and eGFR are more strongly associated with future risk of ESKD. null Research design and methods null Using data from a multicenter observational cohort study of people with type 2 diabetes, we evaluated the association of percentage change in urine...
Source
#1Masayuki YamanouchiH-Index: 17
#2Kengo Furuichi (Kanazawa Medical University)H-Index: 6
Last. Takashi Wada (Kanazawa University)H-Index: 61
view all 33 authors...
BACKGROUND Prognosticating disease progression in patients with diabetic kidney disease (DKD) is challenging, especially in the early stages of kidney disease. Anemia can occur in the early stages of kidney disease in diabetes. We therefore postulated that serum hemoglobin concentration, as a reflection of incipient renal tubulointerstitial impairment, can be used as a marker to predict DKD progression. METHODS Drawing on nationally representative data of patients with biopsy-proven DKD, 246 pat...
Source
#1Reiko Okubo (University of Tsukuba)H-Index: 4
#2Masahide Kondo (University of Tsukuba)H-Index: 21
Last. Kunihiro Yamagata (University of Tsukuba)H-Index: 51
view all 16 authors...
Objectives Chronic kidney disease (CKD) is a significant public health problem. An advanced, or innovative, CKD care system of clinical practice collaboration among general physicians (GPs), nephrologists, and other healthcare workers achieved behavior modification in patients with Stage 3 CKD in the Frontier of Renal Outcome Modifications in Japan (FROM-J) study. This behavior modification intervention consisted of educational sessions on nutrition and lifestyle, as well as encouragement of pat...
Source
#1Haruki Watanabe (Okayama University)H-Index: 8
#2Ken Ei Sada (Okayama University)H-Index: 19
Last. Hirofumi Makino (Okayama University)H-Index: 98
view all 12 authors...
A novel patient cluster in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) may be identified in Japan. We performed multiple correspondence and cluster analysis regarding 427 clinically diagnosed AAV patients excluding eosinophilic granulomatosis with polyangiitis. Model 1 included the ANCA phenotype, items of the Birmingham Vasculitis Activity Score, and interstitial lung disease; model 2 included serum creatinine (s-Cr) and C-reactive protein (CRP) levels with model 1 co...
Source
#1Ryosuke Kikuchi (Nagoya University)H-Index: 20
#2Naotake Tsuboi (Fujita Health University)H-Index: 2
Last. Seiichi Matsuo (Nagoya University)H-Index: 75
view all 18 authors...
BackgroundEffective prognostic markers are needed for antineutrophil cytoplasmic antibody-associated vasculitis (AAV). This study evaluated the clinical associations of serum vascular endothelial g...
Source
#1Jeroen V. Koomen (UMCG: University Medical Center Groningen)H-Index: 3
#2Jasper Stevens (UMCG: University Medical Center Groningen)H-Index: 11
Last. Hiddo J.L. Heerspink (UMCG: University Medical Center Groningen)H-Index: 70
view all 14 authors...
AIM To evaluate whether atrasentan plasma exposure explains between-patient variability in urinary albumin-to-creatinine ratio (UACR) response, a surrogate for kidney protection, and B-type natriuretic peptide (BNP) response, a surrogate for fluid expansion. METHODS Type 2 diabetic patients with chronic kidney disease (n = 4775) received 0.75 mg atrasentan for 6 weeks in the active run-in period. Individual area under the concentration-time-curve (AUC) was estimated using a population pharmacoki...
Source
#1Kenichi Shikata (Okayama University)H-Index: 51
#2Masakazu Haneda (Asahikawa Medical University)H-Index: 31
view all 15 authors...
AIMS/INTRODUCTION We evaluated the efficacy of multifactorial intensive treatment (IT) on renal outcomes in patients with type 2 diabetes and advanced stage of diabetic kidney disease (DKD). MATERIALS AND METHODS Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT-Japan) is a multi-centered, open-labeled, randomized controlled trial with a 5-year follow-up. We randomly assigned 164 patients with advanced stage of DKD (urinary albumin-to-creatinine ratio ≥300 mg/g creatinine,...
2 CitationsSource
#1Seiji Umemoto (Hiroshima University)H-Index: 19
#2Toshio Ogihara (Morinomiya University of Medical Sciences)H-Index: 57
Last. Takao Saruta (Keio: Keio University)H-Index: 84
view all 9 authors...
BACKGROUND: In the trial known as COPE (Combination Therapy of Hypertension to Prevent Cardiovascular Events) three benidipine (a calcium channel blocker; CCB) regimens were compared. Hypertensive Japanese outpatients aged 40-85 years (n=3,293) who did not achieve the target blood pressure of <140/90 mmHg with benidipine 4 mg/day were treated with the diuretic thiazide (n=1,094) or a beta-blocker (n=1,089) or an additional angiotensin receptor blocker (ARB; n=1,110). A significantly higher incid...
Source
#1Jeroen V. Koomen (UMCG: University Medical Center Groningen)H-Index: 3
#2Jasper Stevens (UMCG: University Medical Center Groningen)H-Index: 11
Last. Hiddo J.L. Heerspink (UNSW: University of New South Wales)H-Index: 70
view all 14 authors...
Atrasentan, an endothelin receptor antagonist, showed clinically significant albuminuria reduction with minimal signs of fluid retention in phase II trials. We evaluated whether plasma exposure was associated with long-term outcomes for kidney protection and heart failure in the phase III SONAR trial (n = 3668) in type 2 diabetics with chronic kidney disease. A population pharmacokinetic model was used to estimate plasma exposure of atrasentan 0.75 mg/day. Parametric time-to-event models were us...
Source
#1Haruki Watanabe (Okayama University)H-Index: 8
#2Ken Ei Sada (Okayama University)H-Index: 19
view all 12 authors...
AbstractObjectives: We evaluated the effectiveness of cyclophosphamide for patients with microscopic polyangiitis and granulomatosis with polyangiitis.Methods: Patients treated with cyclophosphamid...
1 CitationsSource